Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme preparation presented as an injectable solution for intravenous use. It treats acute intermittent porphyria attacks in patients with a confirmed diagnosis of acute porphyria. GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Normosang is used to manage acute porphyria disorders by supplying exogenous heme and reducing toxic precursor buildup. - Acute intermittent porphyria: shortens the duration and severity of attacks. - Acute hepatic porphyria: helps control neurovisceral symptoms during crises. - Porphyria‑related neurovisceral attacks: mitigates pain, nausea and autonomic dysfunction.

Common Side Effects: - Infusion site pain or phlebitis. - Nausea or vomiting. - Headache. - Fever or chills. - Transient hypertension.

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions. - Hemolysis, especially in patients with G6PD deficiency. - Acute renal impairment or failure. - Severe hypotension. - Thrombophlebitis extending beyond the infusion site.

Precautions should be observed when administering Normosang to ensure patient safety. - Monitor liver function: assess hepatic enzymes before and during therapy. - Monitor renal function: check creatinine and urine output regularly. - Assess for iron overload: avoid repeated high‑dose courses without evaluation. - Avoid in patients with known hypersensitivity to hemin or its excipients. - Use under specialist supervision: administration should be directed by a physician experienced in porphyria management. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Hemin may interact with other medicines that affect porphyrin metabolism or coagulation. Major Interactions (Avoid): - Barbiturates (e.g., phenobarbital): can exacerbate porphyrin accumulation. - Sulfonamide antibiotics: increase risk of porphyria exacerbation. - Certain anticonvulsants (e.g., phenytoin, carbamazepine): may trigger attacks.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may alter heme synthesis dynamics. - Iron supplements: risk of iron overload when combined with repeated hemin dosing. - Anticoagulants (e.g., warfarin): monitor INR as hemin can affect clotting parameters.